# Pfizer (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/pfizer-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 47.4 |
| Citations | 7,955,704 |
| City | New York |
| Country | US |
| Description | Pfizer (United States) is a research organisation in New York, US. OpenAlex records 45,009 works and 7,955,704 citations for it. 13,914 researchers list it as their most recent affiliation. |
| Homepage | http://www.pfizer.com/ |
| OpenAlex ID | https://openalex.org/I180857899 |
| Region | New York |
| Researchers | 13,914 |
| ROR ID | https://ror.org/01xdqrp08 |
| Type | company |
| Works | 45,009 |

## University papers

Showing 12 of 195.

- [Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease](https://scholariq.org/papers/gut-flora-metabolism-of-phosphatidylcholine-promotes-cardiovascular-disease/)
- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [FinnGen provides genetic insights from a well-phenotyped isolated population](https://scholariq.org/papers/finngen-provides-genetic-insights-from-a-well-phenotyped-isolated-population/)
- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer](https://scholariq.org/papers/first-line-crizotinib-versus-chemotherapy-in-i-alk-i-positive-lung-cancer/)
- [Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis](https://scholariq.org/papers/antipsychotic-induced-weight-gain-a-comprehensive-research-synthesis/)
- [Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force](https://scholariq.org/papers/conjoint-analysis-applications-in-health-a-checklist-a-report-of-the-ispor-good/)
- [Burden of Gastrointestinal Disease in the United States: 2012 Update](https://scholariq.org/papers/burden-of-gastrointestinal-disease-in-the-united-states-2012-update/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19](https://scholariq.org/papers/an-oral-sars-cov-2-m-sup-pro-sup-inhibitor-clinical-candidate-for-the-treatment/)
- [Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis](https://scholariq.org/papers/development-and-clinical-application-of-a-rapid-igm-igg-combined-antibody-test/)

## University researchers

- [Joseph C. Cappelleri](https://scholariq.org/researchers/joseph-c-cappelleri/)
- [Marco DiBonaventura](https://scholariq.org/researchers/marco-dibonaventura/)
- [Brett Hauber](https://scholariq.org/researchers/brett-hauber/)
- [David Gruben](https://scholariq.org/researchers/david-gruben/)
- [José Alvir](https://scholariq.org/researchers/jose-alvir/)
- [Jack Mardekian](https://scholariq.org/researchers/jack-mardekian/)
- [Justin L. Grodin](https://scholariq.org/researchers/justin-l-grodin/)
- [Feng Ye](https://scholariq.org/researchers/feng-ye/)
- [Christine L. Baker](https://scholariq.org/researchers/christine-l-baker/)
- [David Lévy](https://scholariq.org/researchers/david-levy/)
- [Amy Cha](https://scholariq.org/researchers/amy-cha/)
- [Stephen P. Berasi](https://scholariq.org/researchers/stephen-p-berasi/)
- [Yun Zhang](https://scholariq.org/researchers/yun-zhang/)
- [Paulette Negron Ericksen](https://scholariq.org/researchers/paulette-negron-ericksen/)

## University top topics

Showing 8 of 25.

- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Pneumonia and Respiratory Infections](https://scholariq.org/topics/pneumonia-and-respiratory-infections/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Statistical Methods in Clinical Trials](https://scholariq.org/topics/statistical-methods-in-clinical-trials/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.